🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 63 Shanghai 52 Guangzhou 40 Hangzhou 19 Fuzhou 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines6 Shanghai East Hospital2 MediLink Therapeutics (Suzhou) Co., Ltd.2 Daiichi Sankyo2 Minghui Pharmaceutical (Hangzhou) Ltd2
Site location
Beijing63 Shanghai52 Guangzhou40 Hangzhou19 Fuzhou19
All 68 locations
Target enrolment
to

Trials with a site in Shanghai

52 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
NCT07508761Advanced Solid Tumor
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2
52
Shanghai
2026-06-16
Not yet open
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
NCT07582822Advanced Solid Tumor
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
A Study of PLB-002 in Advanced Solid Tumors
NCT07304128Advanced Solid Tumor
Primelink BioTherapeitics(ShenZhen) Limited
Phase 1
100
Shanghai
2026-02-06
Recruiting
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
NCT07298772Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
198
Shanghai
2026-01-07
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
NCT07256782Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
444
Shanghai
2025-10-24
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Recruiting
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
NCT06682780Advanced Solid Tumor
LaNova Medicines Limited
Phase 1/2
320
Shanghai
2025-09-17
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
NCT06992713Advanced Solid Tumor
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase 1
36
Nanjing, Beijing, Shanghai
2025-06-18
Recruiting
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
NCT06936735Advanced Solid Tumor
Hansoh BioMedical R&D Company
Phase 1
502
Shanghai
2025-05-29
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
NCT06772415Advanced Solid Tumor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
Daiichi Sankyo
Phase 2
200
Changsha, Shanghai
2025-01-06
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Recruiting
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
NCT06426680Advanced Solid Tumor
Innolake Biopharm
Phase 1
240
Shanghai
2024-10-30
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
NCT07110883Advanced Solid Tumor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Beijing, Guangzhou, Shanghai
2024-07-01
Recruiting
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
NCT06298058Advanced Solid Tumor
Shanghai Institute Of Biological Products
Phase 1
144
Shanghai
2024-05-09
Recruiting
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
NCT06332170Advanced Solid Tumor
Hansoh BioMedical R&D Company
Phase 1
610
Shanghai
2024-04-26
Active, closed
A Study of MHB039A for Advanced Solid Tumor
NCT06345482Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
196
Shanghai
2024-04-16
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Beijing, Changsha, Shanghai
2024-03-05
Recruiting
A Study of HC006 in Subjects With Advanced Solid Tumors
NCT06304571Advanced Solid Tumor
HC Biopharma Inc.
Phase 1
76
Shanghai
2024-02-27
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
NCT05916248Advanced Solid Tumor
Ruijin Hospital
Phase EARLY_PHASE1
34
Shanghai
2023-12-20
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
NCT06225856Advanced Solid Tumor, Hematological Malignancy
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Recruiting
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
NCT06072989Advanced Solid Tumor
Shanghai East Hospital
Phase 1
24
Shanghai
2023-10
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Active, closed
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
NCT05990452Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
261
Shanghai
2023-08-28
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Beijing, Jinan, Neijiang, Shanghai
2023-08-18
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Active, closed
A Study of MHB036C for Advanced Solid Tumor
NCT06373406Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2023-05-26
Active, closed
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
NCT06299124Breast Cancer, Advanced Solid Tumor
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
30
Shanghai
2023-04-01
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Recruiting
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
NCT05911464Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
248
Shanghai
2023-03-02
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
NCT05038150Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Shanghai, Chengdu
2023-01-16
Active, closed
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
NCT05621486Advanced Solid Tumor
Shanghai East Hospital
Phase 1
36
Shanghai
2022-09-14
Recruiting
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
NCT05306132Advanced Solid Tumor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Recruiting
A Study of CM350 in Patients With Advanced Solid Tumors
NCT05263960Advanced Solid Tumor
Keymed Biosciences Co.Ltd
Phase 1/2
248
Chengdu, Shanghai
2022-04-21
Active, closed
A Study of ILB2109 in Patients With Advanced Solid Malignancies
NCT05278546Advanced Solid Tumor
Innolake Biopharm
Phase 1
48
Jinan, Shanghai
2022-04-11
Recruiting
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
NCT05205850Advanced Solid Tumor
RemeGen Co., Ltd.
Phase 1/2
135
Shanghai, Hangzhou
2022-03-03
Recruiting
A Study of HS-20089 in Patients With Advanced Solid Tumors
NCT05263479Advanced Solid Tumor
Shanghai Hansoh Biomedical Co., Ltd
Phase 1
177
Shanghai
2022-01-05
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
NCT04785196Liposarcoma, Advanced Solid Tumor
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

42 of the 52 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 52 studies
PhaseStudiesRecruitingShare
Phase 1312659.6%
Phase 1/2181434.6%
Phase EARLY_PHASE1223.8%
Phase 2101.9%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
BeOne Medicines66
Daiichi Sankyo21
Eli Lilly and Company21
Hansoh BioMedical R&D Company22
Innolake Biopharm21
MediLink Therapeutics (Suzhou) Co., Ltd.22
Minghui Pharmaceutical (Hangzhou) Ltd20
Shanghai East Hospital21
Ascentage Pharma Group Inc.11
Axter Therapeutics (Beijing) Co., Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.